Peptide Initiative

Peptides · Peptide comparison

PACAP-38 vs VIP (Vasoactive Intestinal Peptide)

Neuroprotective polypeptide with potent anti-inflammatory and cytoprotective properties discovered in 1989

Endogenous neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangePACAP-3810–10 pmol/kg/minVIP (Vasoactive Intestinal Peptide)50–50 mcg
FrequencyPACAP-38Once dailyVIP (Vasoactive Intestinal Peptide)Once daily
AdministrationPACAP-38Intravenous infusionVIP (Vasoactive Intestinal Peptide)Intravenous infusion
Cycle lengthPACAP-38Ongoing/indefiniteVIP (Vasoactive Intestinal Peptide)Ongoing/indefinite
Onset speedPACAP-38Moderate (1-2 weeks)VIP (Vasoactive Intestinal Peptide)Moderate (1-2 weeks)
Evidence levelPACAP-38Strong human trials (Phase 3 or FDA approved)VIP (Vasoactive Intestinal Peptide)Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Neuroprotection

PACAP-3892%
VIP (Vasoactive Intestinal Peptide)78%

Anti-Inflammatory

PACAP-3885%
VIP (Vasoactive Intestinal Peptide)85%

Migraine Research

PACAP-3888%
VIP (Vasoactive Intestinal Peptide)No recorded rating

Cardiovascular

PACAP-38No recorded rating
VIP (Vasoactive Intestinal Peptide)88%

Technical data

Compound specifications

PACAP-38

Molecular formula
C203H331N63O53S
Molecular weight
~4534 Da
Half-life
Very short plasma half-life (minutes); rapid enzymatic degradation
Bioavailability
IV: systemic; Intranasal: direct CNS access bypassing BBB; poor oral bioavailability
CAS number
137061-48-4

VIP (Vasoactive Intestinal Peptide)

Molecular formula
C147H237N43O43S
Molecular weight
3325.83 Da
Half-life
Approximately 1-2 minutes in plasma (rapid enzymatic degradation)
Bioavailability
IV: 100%; Inhaled: local pulmonary delivery; short systemic half-life
CAS number
37221-79-7

Protocols

Dosing compared

PACAP-38

Intravenous

  • 10 pmol/kg/minContinuous infusion · 20-minute single infusionStandardized human experimental-medicine provocation dose; 10 pmol/kg/min over 20 min was selected as the optimal/maximum tolerated rate after dose-finding (5-20 pmol/kg/min) and is reproduced across headache-model trials [6][7][8]. Used as a research provocation agent, not an approved therapeutic.

VIP (Vasoactive Intestinal Peptide)

Subcutaneous injection

  • 50 mcgTwice daily (morning and evening) · Ongoing per protocolCommon research/community practice dose for systemic/peripheral effects (approx., not from a controlled trial).

Inhaled

  • 50 mcg per inhalation (200 mcg/day); 100 mcg single acute doseFour inhalations daily · 12 weeks (chronic study)Inhaled aviptadil in primary pulmonary hypertension: 4 inhalations/day; single 100 mcg dose used for acute vasoreactivity testing [7].

Intravenous infusion

  • 50 → 100 → 150 pmol/kg/hr (ascending over 3 days)12-hour infusion daily · 3 consecutive daysAviptadil (ZYESAMI) dose-escalation regimen in critical COVID-19 respiratory failure trials [6]. Hospital/investigational only.

Applications

Best suited for

PACAP-38

Neuroprotection research
PACAP-38 is particularly well-suited for individuals focused on neuroprotection research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Stroke and traumatic brain injury investigation
PACAP-38 is particularly well-suited for individuals focused on stroke and traumatic brain injury investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Migraine pathophysiology studies
PACAP-38 is particularly well-suited for individuals focused on migraine pathophysiology studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory mechanism research
PACAP-38 is particularly well-suited for individuals focused on anti-inflammatory mechanism research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

VIP (Vasoactive Intestinal Peptide)

Pulmonary arterial hypertension research
VIP (Vasoactive Intestinal Peptide) is particularly well-suited for individuals focused on pulmonary arterial hypertension research. [2][19] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
ARDS and respiratory failure investigation
VIP (Vasoactive Intestinal Peptide) is particularly well-suited for individuals focused on ards and respiratory failure investigation. [1] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory therapy development
VIP (Vasoactive Intestinal Peptide) is particularly well-suited for individuals focused on anti-inflammatory therapy development. [13][18] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Neuroprotection studies
VIP (Vasoactive Intestinal Peptide) is particularly well-suited for individuals focused on neuroprotection studies. [15][16] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

PACAP-38

Common

  • Flushing
  • Tachycardia
  • Gastrointestinal Effects
  • Transient Warmth Sensation

Uncommon

  • Headache and Migraine Triggering
  • Hypotension

Serious

  • Systemic Hypotension and Cardiovascular Effects
  • Systemic Inflammatory Activation

VIP (Vasoactive Intestinal Peptide)

Common

  • Facial Flushing
  • Diarrhea
  • Nausea

Uncommon

  • Hypotension
  • Tachycardia
  • Cardiovascular Effects

Serious

  • Hypotension
  • Severe Flushing and Facial Erythema

Research status

Safety & evidence

PACAP-38

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
PACAP-38 shows good tolerability in Phase II trials for migraine and pain conditions with minimal serious adverse events at IV doses of 2-6 mcg/kg. Primary side effects are transient flushing and headache (10-15% of subjects), likely related to vasodilation. Cardiovascular effects include mild heart rate increase and blood pressure changes, monitored in clinical settings. No carcinogenicity or teratogenicity in animal models; limited long-term safety data in humans.

Contraindications

  • Active migraine or headache disorder (PACAP-38 is a potent migraine trigger)
  • Uncontrolled hypotension or cardiovascular instability
  • Not approved for clinical use outside research settings
  • Insufficient data for pregnancy and lactation safety

VIP (Vasoactive Intestinal Peptide)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
VIP (Vasoactive Intestinal Peptide) is a 28-amino acid endogenous neuropeptide [8] with moderate evidence from Phase 1-2 human clinical trials. The synthetic pharmaceutical form (aviptadil/RLF-100) received FDA fast-track designation for COVID-19-associated ARDS, [24] indicating recognition of its therapeutic potential. Critical safety considerations: VIP is a potent vasodilator that causes dose-dependent hypotension and compensatory tachycardia [6][10][11]—hemodynamic monitoring is essential during IV administration. Common side effects include facial flushing and diarrhea from its GI effects. [6] Phase 2b/3 COVID-19 ARDS trials (196 patients) reported NO serious drug-related adverse events, [1] a favorable safety signal. However, individual responses to vasodilation vary significantly based on baseline cardiovascular status, medications, and underlying conditions. The peptide's short plasma half-life (1-2 minutes) limits systemic accumulation. [10] Inhaled VIP shows excellent local tolerability for pulmonary applications with minimal systemic absorption [18][19].

Contraindications

  • Uncontrolled hypotension or hemodynamic instability
  • Severe cardiac decompensation
  • Not approved for clinical use outside of trials
  • Insufficient data for pregnancy and lactation safety

Decision guide

Which is right for you?

PACAP-38

Choose PACAP-38 if…

  • Neuroprotection research
  • Stroke and traumatic brain injury investigation
  • Migraine pathophysiology studies
  • Anti-inflammatory mechanism research

VIP (Vasoactive Intestinal Peptide)

Choose VIP (Vasoactive Intestinal Peptide) if…

  • Pulmonary arterial hypertension research
  • ARDS and respiratory failure investigation
  • Anti-inflammatory therapy development
  • Neuroprotection studies